Avara Pharmaceutical Services, a world class contract development and manufacturing organization (CDMO), has signed an agreement with Pfizer Inc. to acquire the Liscate, Italy sterile manufacturing facility.
“This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand,” stated Timothy C. Tyson, Chairman and CEO.
Avara Pharmaceutical Services is a contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing and packaging of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.
Avara Pharmaceutical Services now has six sites. Two in the US, including the corporate HQs; one in Puerto Rico, one in the UK, one in Ireland and this new additional site in Italy.